Company intelligence / Profile preview

AtriCure, Inc.

Mason, Ohio, United Statesatricure.com ↗

Ownership: Public · ATRC
Employees: ~1300
Development stage: Other

Overview

AtriCure's Isolator Synergy Ablation System is FDA-approved for persistent Afib treatment. The CONVERGE IDE clinical trial showed an 18% difference in favor of the hybrid Convergent procedure compared to endocardial catheter ablation alone for persistent Afib patients. The company is currently conducting the LeAAPS clinical trial, which will enroll up to 6,500 patients at up to 250 centers worldwide to evaluate the AtriClip system for stroke prevention in cardiac surgery patients[6][8].

Therapeutic areas: CardiovascularNeurology
Modalities: Surgical devicesablation systemsleft atrial appendage management devices
Industry: Surgical Medical Devices

Partnerships

Population Health Research Institute (PHRI)

Financials

Market cap: $3.1B
Total revenue: $534.5M
Enterprise value: $3B

Beyond the preview

Go deeper on AtriCure, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtriCure, Inc..